Steatotic liver disease and HIV: an agenda for 2030
- PMID: 38972321
- DOI: 10.1016/S2352-3018(24)00097-3
Steatotic liver disease and HIV: an agenda for 2030
Abstract
People living with HIV are particularly susceptible to developing metabolic disorders, including metabolic dysfunction-associated steatotic liver disease and other forms of SLD. However, people living with HIV have been historically excluded from clinical trials and large cohort studies of SLD. Therefore, our understanding of the risk factors and natural history of SLD in this population is poor. Moreover, relevant knowledge gaps on the epidemiology and barriers for adequate health care, such as stigma, hamper adequate responses to the ongoing HIV and SLD syndemic. This Viewpoint provides a comprehensive perspective on how to tackle SLD in people living with HIV by examining the role of social determinants of health in the development of liver disease and metabolic syndrome comorbidities among this population, emphasising the importance of prioritising SLD management, summarising the most urgent needs in the field, and offering recommendations for advancing research to fill key data gaps and protect liver health of people living with HIV.
Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests JMP reports having received consulting fees from Boehringer Ingelheim, MSD and Novo Nordisk. He has received speaking fees from Gilead, Intercept, and Novo Nordisk, and travel expenses from Gilead, Rubió, Pfizer, Astellas, MSD, CUBICIN, and Novo Nordisk. He has received educational and research support from Madrigal, Gilead, Pfizer, Astellas, Accelerate, Novartis, AbbVie, ViiV, and MSD. CR reports honoraria for speaking activities from ViiV Healthcare. GG reports speaking fees from ViiV Healthcare. AB acknowledges having received consulting fees from Boehringer Ingelheim and speaking fees by GE Healthcare and Hologic. GW received research grants from Gilead Sciences and Roche Diagnostics. MBB has received grant support from National Institute of Health, US Centers for Disease Control and Prevention/National Institute for Occupational Safety and Health, Pfizer, The Kinetix Group, Histoindex, and serves as a consultant for The Kinetix Group, Madrigal, Pfizer, Theratechnologies, Fibronostics, Novo Nordisk, and GSK. JN has received honoraria, speaking fees, and financial support for attending conferences from AbbVie, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, and ViiV Healthcare, and consulting fees from ViiV Healthcare, Gilead Sciences, Janssen Cilag, and Merck Sharp & Dohme, outside the submitted work. JVL acknowledges grants from AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Madrigal, MSD, Novo Nordisk, Pfizer, and Roche Diagnostics; speaker fees from AbbVie, Echosens, Gilead Sciences, Janssen, Moderna, MSD, Novo Nordisk, and Pfizer; and consulting fees from Echosens, NovoVax, GSK, Novo Nordisk, and Pfizer, all outside the current work. JVL also acknowledges participation on the advisory board for the “Same-visit hepatitis C testing and treatment to accelerate cure among people who inject drugs (The QuickStart Study): a cluster randomised control trial–Australia” trial; had roles in the following committees: Member, European Association for the Study of the Liver, Public Health and Policy Committee; Healthy Livers, Health Livers (formed by AASLD, ALEH, APASL, European Association for the Study of the Liver) Global NASH Council; and was the Co-chair of HIV Outcomes. All other authors declare no competing interests.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
